XELOX with Dostarlimab after chemoradiation for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug dostarlimab (a checkpoint inhibitor) to standard chemotherapy (XELOX) after chemoradiation improves outcomes for patients with locally advanced rectal cancer that is not MSI-high. You may be eligible if your tumor has specific genetic features called pMMR/MSS or MSI-low, and you have not received prior chemotherapy or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma that is within about 16 cm of the anal opening
- Your cancer stage is T3-4 N0 M0, or any N+ with at least 3 lymph nodes >0.5 cm or 1 node >1 cm on imaging
- Your tumor is pMMR/MSS or MSI-low (not MSI-high)
- Your performance status is 0 or 1 (fully active or slightly limited)
- You have not had prior chemotherapy or radiation for this cancer
- Your blood counts and kidney/liver function are within defined normal limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
This Phase 2 study looks at a modified “sandwich” treatment sequence for people with locally advanced rectal cancer—aiming to control the cancer before and after surgery. It may help you if you’re eligible and can follow the study’s treatment and safety requirements.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.